Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region - Global Forecast to 2030
Updated on : April 10, 2023
The global transplant diagnostics market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to grow at a CAGR of 7.4% from 2023 to 2030.
The new research report includes an analysis of market industry trends. The new research report includes industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and market buying behavior. Infectious diseases have a greater impact. The number of people with end-stage organ failure is increasing, and as transplant technology advances, a higher percentage of patients are now eligible for organ transplants. These two things cause an increase in demand. Increase government and private funding for transplantation, as well as conduct numerous organ transplant awareness programs.
Transplant Diagnostics Market Dynamics
Drivers: The number of transplant surgeries is increasing.
Transplants are becoming a realistic technique of bringing life or rebirth to a human as various technology and screening methods, such as genetic profiling and cross-matching, gain acceptability. The increased number of transplant procedures in important countries may be contributing to the transplant market's rising CAGR. In 2021, for example, 41,354 organ transplants were conducted in the United States, whereas 5,273 organ transplants were performed in France. Tuberculosis, end-stage renal failure, and liver cirrhosis are common among the elderly, necessitating transplant surgery.
Opportunities: Increasing public understanding of organ donation and transplantation.
The American Transplant Foundation launched the DLA Awards in 2022 to reward programmes that raise public awareness about organ donation and transplantation. The Organ Receiving and Giving Awareness Network (India) held an awareness programme in 2021 with the goal of increasing public readiness to give organs for transplantation operations in India.Long runs of 3km, 5km, and 10km are organised in the United States to raise awareness of organ transplants among the general public and to make people aware of the importance of giving life to others.
Challenges: There is a large mismatch between the number of organ donors and the number of organs needed.
There is a considerable disparity between the number of organs donated each year and the number of organ donations required. The low number of organs donated each year throughout the world is mostly owing to stringent government enforcement, minimal medical reimbursements for live organ donors, and a lack of public knowledge regarding organ donation.
Restraints: NGS and PCR-based diagnostic tests have high procedure costs.
Transplant diagnostic procedures for histocompatibility testing, blood profiling, and genomic profiling are performed through specialized molecular diagnostic platforms comprised of several state-of-the-art technologies. These technologies are embedded in conventional PCR/NGS instruments and hence the cost of these advanced products is higher.
Market Ecosystem
By technology, During the projection period, the molecular assay technologies segment had the greatest share of the transplant diagnostics market.
Molecular assay technologies held the greatest proportion of the market in 2023. This category is expected to grow at an 8.0% CAGR from USD 4,166.0 million in 2023 to USD 6,156.9 million in 2030. Donor-recipient compatibility testing is performed using molecular tests in transplant diagnostic processes. The increased demand for molecular tests during transplant diagnostic procedures is mostly due to the technical advantages afforded by these assays over non-molecular assays, such as high procedural effectiveness, multiple sample analysis, and real-time analysis.
By End User, During the forecast period, independent reference laboratories are predicted to grow at the quickest rate in the transplant diagnostics market.
Independent reference laboratories would have a bigger market share of 58.65% in 2023. This end-user category is expected to grow from USD 2,668.8 in 2023 to USD 4,233.9 in 2030. During the projection period, this end-user category is also predicted to increase at the fastest CAGR of 8.0%. The fast modernization and automation of diagnostic laboratories, as well as the expanding number of research and development activities, can be contributed to the substantial proportion of this category.
By Product & Services, The Reagents & Consumables category dominates the transplant diagnostics industry.
In 2023, Reagents & Consumables will account for 72.2% of the market. This Product & Service category is expected to grow from USD 3,265.2 million in 2023 to USD 5,131.0 million in 2030. The majority of transplant diagnostics are made up of reagents and consumables. Expansion of molecular assay technology application frontiers in transplant diagnostics, with increased patient emphasis on successful and early patient profiling during organ transplantation.
By Application, During the projection period, infectious disease tests accounted for the biggest proportion of the transplant diagnostics market.
Infectious illness testing is expected to grow from USD 2,344.0 million in 2023 to USD 3,764.3 million in 2030.A number of factors, including ongoing technological advancements in the field of molecular assay techniques, the increasing adoption of these techniques for pathogen detection and histocompatibility testing, and the rising incidence of infectious chronic diseases, are assisting this segment's rapid growth.
During the projected period, North America is predicted to be the largest region in the transplant diagnostics market.
In 2023, North America, which comprised the United States and Canada, had 45.4% of the market. Factors such as sickness frequency, population ageing, and the emergence of infectious illnesses all contribute to North America's significant contribution.
Because of increased organ donations and varied governmental and private reimbursement programmes, the APAC area is developing at the fastest CAGR of 8.3%.
As of 2021, prominent players in the market are include bioMérieux SA (France), Becton, Dickinson, and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US) among others.
Transplant Diagnostics Market Report Scope:
This report categorizes the global transplant diagnostics market into following segments & sub-segments:
By Technology
- Molecular assay technologies
- PCR-based molecular assays
- Real-time PCR
- Sequence-specific primer-PCR
- Sequence-specific Oligonucleotide-PCR
- Other PCR-based molecular assays
- Sequencing based molecular assays
- Sanger sequencing
- Next generation sequencing
- Other sequencing based molecular assays
- Non molecular assays technologies
By Product & Service
- Reagents & Consumables
- Instruments
- Software & Services
By Application
- Diagnostic application
- Pre-transplantation Diagnostics
- Infectious Disease testing
- Histocompatibility testing
- Blood profiling
- Post -transplantation Diagnostics
- Pre-transplantation Diagnostics
- Research applications
By transplant type
- Solid Organ Transplantation
- Kidney transplantation
- Liver transplantation
- Heart transplantation
- Lung transplantation
- Pancrease transplantation
- Other Organs transplantation
- Stem Cell transplantation
- Soft tissue transplantation
- Bone marrow transplantation
By End User
- Hospitals and Transplant centers
- Research &Academic Institutes
- Independent reference laboratories
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In February 2023, BD received FDA approval for BD Onclarity HPV assay in the serology testing segment
- In March 2023 BioRad received AQAC International and AFNOR approval for its iQ-Check kits.
- Hoffmann-La Roche Ltd. unveiled Cobas Infinity edge, a cloud-based point-of-care platform that is available everywhere, in January 2023. Practitioners in the healthcare industry can manage patient data thanks to advanced technology. This has aided the business in diversifying its product offering.